loading page

NF-κB inhibitor suppresses experimental autoimmune neuritis in mice via declining macrophages polarization to M1 type
  • +4
  • Donghui Shen,
  • Fengna Chu,
  • Yue Lang,
  • Chao Zheng,
  • Chunrong Li,
  • Xiangyu Zheng,
  • Jie Zhu
Donghui Shen
Jilin University First Hospital
Author Profile
Fengna Chu
Jilin University First Hospital
Author Profile
Yue Lang
Jilin University First Hospital
Author Profile
Chao Zheng
First Hospital of Jilin University
Author Profile
Chunrong Li
Jilin University First Hospital
Author Profile
Xiangyu Zheng
Jilin University First Hospital
Author Profile
Jie Zhu
Jilin University First Hospital
Author Profile

Abstract

Guillain–Barre’ syndrome (GBS) is an acute inflammatory and immune-mediated demyelinating disease of peripheral nervous system (PNS). Macrophages playing a central role in its animal model, experimental autoimmune neuritis (EAN) has been well-accepted. Additionally, NF-κB inhibitors has been used to treat cancers and showed beneficial effects. Here we investigated the therapeutic effect of M2 macrophage and NF-κB pathway is correlated with macrophages activation in experimental autoimmune neuritis (EAN) in C57BL/6 mice. We demonstrated that M2 macrophage transfusion can alleviate the clinical symptoms of EAN by reducing the proportion of M1 macrophage in the peak period, inhibiting the phosphorylation of NF-κB p65. The NF-κB inhibitor (BAY-11-7082) could alleviate the clinical symptoms of EAN and shorten the duration of symptoms by reducing the proportion of M1 macrophages and the expression of pro-inflammatory cytokines. Consequently, BAY-11-7082 exhibits strong potential as a therapeutic strategy for ameliorating EAN by influencing the balance of M1/M2 macrophages and inflammatory cytokines.

Peer review status:ACCEPTED

22 Apr 2021Submitted to Clinical & Experimental Immunology
23 Apr 2021Submission Checks Completed
23 Apr 2021Assigned to Editor
28 Apr 2021Reviewer(s) Assigned
20 May 2021Review(s) Completed, Editorial Evaluation Pending
20 May 2021Editorial Decision: Revise Minor
10 Jun 20211st Revision Received
10 Jun 2021Review(s) Completed, Editorial Evaluation Pending
10 Jun 2021Editorial Decision: Accept